Juan José Corte-García, Edurne Fernández de Gamarra-Martínez, Begoña Tortajada-Goitia, Cecilia M Fernández-Llamazares
{"title":"Hospital pharmacy in Spain towards 2030: A national self-assessment of the baseline status and strategic challenges of the SEFH 2030 Project.","authors":"Juan José Corte-García, Edurne Fernández de Gamarra-Martínez, Begoña Tortajada-Goitia, Cecilia M Fernández-Llamazares","doi":"10.1016/j.farma.2026.10.010","DOIUrl":"https://doi.org/10.1016/j.farma.2026.10.010","url":null,"abstract":"<p><p>The 2030 Project of the Spanish Society of Hospital Pharmacy (SEFH 2030 Project) defines 20 strategic challenges for the development of the specialty, together with the standards that allow their achievement to be measured. The baseline degree of implementation of these strategic challenges in hospital pharmacy services in Spain was described, as well as its variability according to hospital type, size, ownership, teaching accreditation and geographical distribution. A cross-sectional observational study was conducted through a national self-assessment questionnaire addressed to the pharmacy services of 374 hospitals listed in the National Hospital Catalogue, categorised by type, ownership, teaching accreditation and size. The questionnaire was completed between May and December 2025 on a dedicated online platform and comprised 100 items corresponding to the 5 most representative standards for each challenge, with 4 response levels ranging from not planned to fully implemented. The 20 challenges were grouped into 4 thematic domains. The degree of implementation was calculated by standard, challenge, domain and overall, and analysed according to hospital category and autonomous community. A total of 199 hospitals responded (53.2%), with response rates ranging from 82.6% to 31.5% depending on hospital category. Overall implementation of the 100 standards was 45.4%. By thematic domain it reached 57.4% in transversal activities, training and research, 51.9% in comprehensive pharmaceutical care, 40.0% in people and professional teams and 34.2% in organisations and health systems. Leadership in clinical safety achieved the highest implementation (73.6%) and open innovation the lowest (18.1%). Implementation ranged from 61.7% in public teaching general hospitals with more than 999 beds to 31.1% in single-specialty centres, and from 53.7% to 28.8% depending on the autonomous community. Variability is observed according to size, ownership and geographical distribution, with consolidated areas (leadership in clinical safety or medicines compounding) alongside gaps in innovation, digital transformation and connection with patients and the community. Data derive from an unverified self-assessment, and the lower participation of private and smaller centres may overestimate overall implementation. These results provide an individual and collective reference for strategic planning and for prioritising improvement actions towards the 2030 horizon.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gabriel Mercadal Orfila, Roberto Collado Borrell, Luis Margusino Framiñan, Ramón Morillo-Verdugo
{"title":"[Translated article] MAPEX-SEFH guide for the implementation of patient-reported outcomes and experience in outpatient hospital pharmacy.","authors":"Gabriel Mercadal Orfila, Roberto Collado Borrell, Luis Margusino Framiñan, Ramón Morillo-Verdugo","doi":"10.1016/j.farma.2026.09.007","DOIUrl":"https://doi.org/10.1016/j.farma.2026.09.007","url":null,"abstract":"<p><p>The integration of patient-reported outcomes (PROMs) and patient-reported experience measures (PREMs) represents a key step toward value-based pharmaceutical care in outpatient hospital pharmacy settings. The MAPEX guideline for the implementation and use of PROMs and PREMs provides a practical framework for their integration into clinical practice, aligned with the Capacity-Motivation-Opportunity (CMO) model. This work synthesizes its main components from an applied perspective, combining available evidence with the strategic principles of the MAPEX project and prioritizing real-world applicability. The guideline proposes a structured and pragmatic approach to the implementation of PROMs and PREMs, linking their use to patient stratification, motivational interviewing, and longitudinal follow-up through dual care models combining face-to-face and digital interventions. It defines criteria for instrument selection, clinical interpretation of results, and the technological and organizational requirements for implementation, as well as key barriers and facilitators. In this context, PROMs and PREMs are positioned as actionable tools that support clinical decision-making, enable personalized pharmacotherapeutic follow-up, and make the impact of pharmaceutical care visible through patient-relevant outcomes. The integration of these instruments within the MAPEX-CMO framework reinforces person-centered, value-based care models and supports a more efficient, personalized, and clinically meaningful approach. Their implementation contributes to consolidating the role of hospital pharmacists in the evaluation of health outcomes and the improvement of patient experience.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
José Ángel Lema-Atán, Elena Lendoiro, Angelines Cruz, Beatriz Bernárdez, María Cobo-Golpe, Nieves Mayo, Miriam Blanco-Ces, Manuel Tourís, Ángela López-Rabuñal, Irene Zarra, Manuel López-Rivadulla, Ana de-Castro-Ríos
{"title":"How safe is occupational exposure to cytostatic drugs? Results from environmental and biological monitoring.","authors":"José Ángel Lema-Atán, Elena Lendoiro, Angelines Cruz, Beatriz Bernárdez, María Cobo-Golpe, Nieves Mayo, Miriam Blanco-Ces, Manuel Tourís, Ángela López-Rabuñal, Irene Zarra, Manuel López-Rivadulla, Ana de-Castro-Ríos","doi":"10.1016/j.farma.2026.09.013","DOIUrl":"https://doi.org/10.1016/j.farma.2026.09.013","url":null,"abstract":"<p><strong>Objective: </strong>Occupational exposure to cytostatic drugs has been associated with acute and chronic toxicity. Despite the publication of guidelines and measures for safety handling, contamination is still reported in most recent studies. The aim of the present work was to assess contamination of cytostatic drugs in a hospital from the North of Spain.</p><p><strong>Methods: </strong>Working surfaces from the Pharmacy and the Onco-Hematology services were tested for gemcitabine, dacarbazine, methotrexate, cyclophosphamide, doxorubicinol, doxorubicin, epirubicin, irinotecan, vinorelbine, etoposide, docetaxel and paclitaxel. Urine samples from workers were also analyzed.</p><p><strong>Results: </strong>Within the Pharmacy service, contamination was detected in 57.6% of the collected samples, with cyclophosphamide and gemcitabine being the most detected compounds. At the Onco-Hematology service, contamination was present in 32.3% of the samples collected from infusion pumps, armchairs and surrounding floors, and in all samples collected from the toilets (all positive for gemcitabine, irinotecan and paclitaxel). Low concentrations (<100 pg/cm<sup>2</sup>) were detected in ≥76% of the contaminated samples in all the locations, except for the outpatients' area bathrooms, where this value was <40%. In addition, 60.7% of vials, blisters and infusion bags sampled were contaminated. Only 2 of the 82 bracelets worn by workers showed contamination with cyclophosphamide. Finally, all the urine samples were negative.</p><p><strong>Conclusions: </strong>Despite the low levels of contamination, it is advisable to carry out monitoring campaigns to maintain workers' awareness and to take corrective actions to minimize occupational exposure.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
María José Otero, Nuria Prieto-Santos, Rita Martín Muñoz, Rebeca Padilla Peinado, José Manuel Caro-Teller, Rocío Montiel Villalonga, Mónica Climente Martí, Monike de Miguel Cascón, Laura Doménech Moral, Judit García Aparicio, Ana Herranz Alonso, Montserrat Pérez Encinas
{"title":"[Translated article] Implementation of safe practices for the use of high-risk medications in Spanish hospitals.","authors":"María José Otero, Nuria Prieto-Santos, Rita Martín Muñoz, Rebeca Padilla Peinado, José Manuel Caro-Teller, Rocío Montiel Villalonga, Mónica Climente Martí, Monike de Miguel Cascón, Laura Doménech Moral, Judit García Aparicio, Ana Herranz Alonso, Montserrat Pérez Encinas","doi":"10.1016/j.farma.2026.09.010","DOIUrl":"https://doi.org/10.1016/j.farma.2026.09.010","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the implementation of safe practices for the use of high-risk medications in Spanish hospitals and to identify priority areas for improvement.</p><p><strong>Methods: </strong>A multicenter descriptive study was conducted to assess the degree of implementation of safe practices included in the Spanish Medication Safety Self-Assessment® for High-Alert Medications. Included were Spanish hospitals that voluntarily completed the questionnaire between April and June 2025. The questionnaire comprises 186 assessment items, some with multiple components (254 in total), organized into eight sections: general practices and specific practices for neuromuscular blocking agents, intravenous potassium, insulins, methotrexate (non-oncological use), antineoplastics, anticoagulants and opioids. Mean scores and the percentages of the maximum possible score were analyzed for the overall questionnaire, each section, and each item or its components.</p><p><strong>Results: </strong>A total of 82 hospitals from 13 autonomous communities participated, most of them public (93.9%), general (97.6%) and teaching hospitals (98.8%). The overall implementation of safe practices was 52.7%, with wide variability among centers (29.7%-81.1%). General practices showed a low level of implementation (41.9%). Among therapeutic groups, the highest scores were observed for antineoplastics (80.5%), followed by neuromuscular blocking agents (64.7%), anticoagulants (61.3%) and insulins (54.8%). Values below 50% were found for opioids (49.8%), intravenous potassium (35.6%) and methotrexate (33.8%). The most widely implemented practices were related to storage (except potassium), dose expression and clinical monitoring. Those with the lowest level of implementation included several high-effectiveness technologies, such as clinical decision support alerts and barcode verification during medication preparation, dispensing and administration, as well as the integration of pharmacists into clinical units, preparation of standardized intravenous solutions in the pharmacy, and medication reconciliation at discharge. Low implementation was also observed in practices related to staff training.</p><p><strong>Conclusions: </strong>The implementation of safe practices for high-risk medications in Spanish hospitals is moderate and heterogeneous, with notable variability across therapeutic groups and processes. These findings provide a useful reference at both national and local levels to prioritize improvement initiatives and to assess the impact of future interventions aimed at reducing medication errors associated with these drugs.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Juan Carlos Del Río-Valencia, Rocío Tamayo-Bermejo, Juan Diego Paradas-Palomo, Beatriz Mora-Rodríguez, Cristina López-Escola
{"title":"Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases.","authors":"Juan Carlos Del Río-Valencia, Rocío Tamayo-Bermejo, Juan Diego Paradas-Palomo, Beatriz Mora-Rodríguez, Cristina López-Escola","doi":"10.1016/j.farma.2026.10.007","DOIUrl":"https://doi.org/10.1016/j.farma.2026.10.007","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to evaluate the effectiveness and safety of pembrolizumab as monotherapy in patients with Non-Small-Cell Lung cancer and brain metastases in real-world clinical practice at tertiary care.</p><p><strong>Material and methods: </strong>A retrospective observational study was conducted at a tertiary hospital in Spain between August 2017 and March 2023. Adult patients with stage IV non-small-cell lung carcinoma and radiologically confirmed brain metastases who received pembrolizumab monotherapy were included. Progression-free survival, overall survival, objective response rate and treatment-related adverse events were analyzed.</p><p><strong>Results: </strong>Among 172 patients treated with pembrolizumab, 45 had brain metastases and 25 received monotherapy. Median progression-free survival was 3 months (95% CI: 2.02-3.97), and median overall survival was 6months (95% CI: 4.37-7.62). The objective response rate was 24%, and the disease control rate was 40%. Treatment-related toxicity of any grade was reported in 64% of patients, with no unexpected safety signals observed.</p><p><strong>Conclusions: </strong>Pembrolizumab monotherapy showed clinical activity and an acceptable safety profile in patients with non-small-cell lung carcinoma and brain metastases treated in routine practice. Larger prospective studies are needed to optimize patient selection in this setting.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149325819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eva Clara López-Diaz, Maria Muñoz-Garcia, Celia Acosta-Cano, Maria Dolores Molina-Mendoza, Miguel Zamorano-Serrano, Virginia Greciano-Greciano, Alfonso Muriel-García, Jose Roberto Penedo-Alonso, Ana Alvarez-Diaz, Eva Delgado-Silveira
{"title":"Transitional care from the emergency department: Impact of a comprehensive pharmacotherapy review in complex chronic patients.","authors":"Eva Clara López-Diaz, Maria Muñoz-Garcia, Celia Acosta-Cano, Maria Dolores Molina-Mendoza, Miguel Zamorano-Serrano, Virginia Greciano-Greciano, Alfonso Muriel-García, Jose Roberto Penedo-Alonso, Ana Alvarez-Diaz, Eva Delgado-Silveira","doi":"10.1016/j.farma.2026.08.011","DOIUrl":"https://doi.org/10.1016/j.farma.2026.08.011","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the impact of a continuity-of-care programme with comprehensive pharmacotherapy assessment for Complex Chronic Patients in the Emergency Department, in terms of pharmacotherapy safety and healthcare resource utilization.</p><p><strong>Methodology: </strong>Prospective intervention study with Control Group. In the Control Group, patients' treatment was reviewed according to standard practice. In the Intervention Group, treatment was review within less than 24 hours of their attendance at the Emergency Department or within 48 hours if the visit occurred on a weekend or public holiday. The intervention consisted of medication reconciliation, a comprehensive pharmacotherapy review, and preparation of recommendation reports at admission. At discharge, reports were sent to Primary Care. After discharge, patients received a follow-up telephone call one month later and an additional follow-up assessment at three months.</p><p><strong>Results: </strong>A total of 151 patients were included in both the intervention and control groups. There was a significant reduction in the number of patients with polypharmacy, anticholinergic burden, potentially inappropriate prescriptions, and reconciliation errors. There was a 20.6% reduction in innapropriate prescribing in the intervention group, particularly for drugs without indication, benzodiazepines, and neuroleptics. Forty-nine percent of the recommendations made by pharmacists were accepted by the medical team. Continuity of care allowed 51.9% to be resolved.</p><p><strong>Conclusion: </strong>Integration of pharmacists into the multidisciplinary Emergency Department team enhances the safety of Complex Chronic Patients, significantly reducing polypharmacy, inappropriate prescribing and anticholinergic burden, although it does not appear to influence the reduction in the use of healthcare resources. Recommendations issued were widely accepted by the medical team.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149325820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
FARMACIA HOSPITALARIAPub Date : 2026-11-01Epub Date: 2026-05-15DOI: 10.1016/j.farma.2026.04.004
Inmaculada Romero-Zayas, María de Arcocha-Torres, Iván Peñuelas, Elena Martínez Montalbán, María Carmen Plancha Mansanet, Antonio de Jesús Fernández Sánchez, Juan Antonio Pérez Iruela
{"title":"Guía de procedimientos radiofarmacéuticos para el marcaje in vitro de leucocitos","authors":"Inmaculada Romero-Zayas, María de Arcocha-Torres, Iván Peñuelas, Elena Martínez Montalbán, María Carmen Plancha Mansanet, Antonio de Jesús Fernández Sánchez, Juan Antonio Pérez Iruela","doi":"10.1016/j.farma.2026.04.004","DOIUrl":"10.1016/j.farma.2026.04.004","url":null,"abstract":"<div><div>This guide outlines the radiopharmaceutical procedure for the <em>in vitro</em> labelling of leukocytes. Scintigraphy using leukocytes labeled with [<sup>99m</sup>Tc]Tc-exametazime or [<sup>111</sup>In]In-oxine is a highly valuable diagnostic tool in infectious and inflammatory diseases due to its high sensitivity and specificity. It is based on established guidelines and consensus protocols, which incorporate the recent Spanish regulations on the extemporaneous preparation of radiopharmaceuticals, this document provides detailed and precise instructions for the safe and effective preparation and quality control of <em>in vitro</em> labeled leukocytes. The clinical indications for leukocyte scintigraphy are described, along with the technical requirements for both facilities and equipment. The various stages of the radiolabelling procedure are developed and substantiated, including blood sample collection, leukocyte fraction separation and isolation, incubation and subsequent radiolabelling with either [<sup>99m</sup>Tc]Tc-exametazime or [<sup>111</sup>In]In-oxine, radiopharmaceutical conditioning for administration, and the necessary quality control procedures. The document concludes with a section describing drug interactions reported in the literature. Two annexes are included, providing example labeling protocols for both radiopharmaceuticals.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 6","pages":"Pages 397-405"},"PeriodicalIF":1.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147949910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
FARMACIA HOSPITALARIAPub Date : 2026-11-01Epub Date: 2026-06-15DOI: 10.1016/j.farma.2026.04.011
Paloma Suárez-Casillas, Marta Mejías-Trueba, José María Gutiérrez-Urbón, Walter A. Goycochea-Valdivia, Elena Varela-Rubio, Olaf Neth, Maria Goretti López-Ramos, Maria Victoria Gil-Navarro, Ana Belén Guisado-Gil
{"title":"Protocolo del estudio PROA-KIDDDs: evaluación del consumo y adecuación del uso del tratamiento antimicrobiano en pediatría y neonatología en España","authors":"Paloma Suárez-Casillas, Marta Mejías-Trueba, José María Gutiérrez-Urbón, Walter A. Goycochea-Valdivia, Elena Varela-Rubio, Olaf Neth, Maria Goretti López-Ramos, Maria Victoria Gil-Navarro, Ana Belén Guisado-Gil","doi":"10.1016/j.farma.2026.04.011","DOIUrl":"10.1016/j.farma.2026.04.011","url":null,"abstract":"<div><h3>Objective</h3><div>To analyze the use of antimicrobials in the pediatric and neonatal population at a national level in order to identify consumption patterns, assess treatment appropriateness, and detect potential areas for improvement in therapeutic management.</div></div><div><h3>Method</h3><div>We designed a retrospective, cross-sectional, multicenter observational study that included neonatal (<<!--> <!-->1 month) and pediatric (<<!--> <!-->15 years) inpatients with at least one active prescription of systemic antibacterials or antifungals. The study consists of two phases. The first phase involves the analysis of antimicrobial consumption through quarterly data collection, expressed as pediatric and neonatal defined daily doses (DDD) per 100 patient-days. A temporal trend analysis will be performed using segmented regression and calculation of the average quarterly percent change with 95% confidence intervals, identifying change points through the Monte Carlo permutation method.</div><div>The second phase focuses on evaluating prescription appropriateness based on indication, antimicrobial selection, timing of administration, dose, frequency, route of administration, treatment duration, monitoring of efficacy and adverse effects, and documentation in the medical record. The review will be conducted by a hospital pharmacist and an infectious diseases specialist, with interobserver verification in 25% of cases. A sample size of 379 patients (270 pediatric and 109 neonatal) has been estimated for this phase. Differences between variables will be analyzed using Student's t-test, Mann–Whitney U test, Chi-squared test, or Fisher's exact test as appropriate. Inter-rater agreement will be assessed using Cohen's Kappa coefficient, and factors associated with differences in appropriateness will be analyzed through binary logistic regression and generalized lineal mixed models.</div></div><div><h3>Discussion</h3><div>This study will allow the identification of antimicrobial consumption patterns and the evaluation of prescription appropriateness in pediatric and neonatal populations, providing objective and comparable information across centers. The findings will help strengthen Antimicrobial Stewardship Programs, serve as a solid basis for future research, and support the development of targeted national strategies, ultimately improving patient safety and helping to curb the progression of antimicrobial resistance.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 6","pages":"Pages 418-424"},"PeriodicalIF":1.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148260012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
FARMACIA HOSPITALARIAPub Date : 2026-11-01Epub Date: 2026-05-14DOI: 10.1016/j.farma.2026.04.003
Robinraja Elango, Russell Martin, Shivanand K. Mutta
{"title":"Orphan drug regulation: a global comparison of the United States Food and Drug Administration, European Medicines Agency, and Japanese pharmaceuticals and medical devices agency approaches","authors":"Robinraja Elango, Russell Martin, Shivanand K. Mutta","doi":"10.1016/j.farma.2026.04.003","DOIUrl":"10.1016/j.farma.2026.04.003","url":null,"abstract":"<div><h3>Objective</h3><div>To perform a comparative review of orphan drug policies and designation criteria implemented by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), assessing their influence on development, approval, and access.</div></div><div><h3>Method</h3><div>A targeted review of legislation, guidance documents, and peer-reviewed analyses from each regulatory body was conducted.</div></div><div><h3>Results</h3><div>The FDA accelerates development via robust tax credits and seven-year market exclusivity, though high pricing remains challenging. The EMA emphasizes unmet medical needs and ten-year exclusivity, ensuring more homogeneous pricing despite slower approvals. Japan's PMDA utilizes specific subsidies and the Sakigake designation to counter “drug loss” and encourage innovation. Despite expedited pathways globally, significant disparities in affordability and patient access persist.</div></div><div><h3>Conclusions</h3><div>While national incentives successfully boost orphan drug approvals, global access inequities remain unresolved. Harmonizing regulatory criteria and promoting international collaboration on evidence requirements are essential for equitable and sustainable access to rare disease therapies worldwide.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 6","pages":"Pages 425-433"},"PeriodicalIF":1.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147943196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}